Quantitative proteomics studies are challenging as high sensitivity and a high degree of selectivity are required to analyze systematically large peptide sets in one single experiment. Quantification of peptides in complex samples can be performed on a quadrupole-orbitrap instrument in MS/MS mode (parallel reaction monitoring, PRM). The high resolving power of this technique dramatically increases the selectivity of the measurements while the trapping capability can be leveraged to boost the sensitivity. Precise quantification as well as large-scale screening in biological samples can be performed using multiplexed analysis in conjunction with stable isotope dilution. In this webinar, Dr. Bruno Domon (Luxembourg Clinical Proteomics Center at CRP-Santé) discusses the principle of quantification using high-resolution/accurate mass (HR/AM) in the context of proteomics experiments. The discussion will focus on the selectivity of the measurements and the limit of quantification. Furthermore, the unique trapping and multiplexing capabilities of the quadrupole/orbitrap instrument as applied to large-scale experiments will be presented.
What You Will Learn
- The main challenges encountered in quantitative analysis of biological samples
- Principle of quantification using high-resolution / accurate mass
- Quantification using parallel reaction monitoring (PRM)
Who Should Attend
- Researchers interested in quantitative proteomics
- Bench scientists analysis involved in the clinical or complex biological samples
- Researchers interested in recent developments of mass spectrometry technology
Dr. Bruno Domon
Dr. Bruno Domon joined the Centre de Recherche Public Santé in Luxembourg to lead the new Clinical Proteomics Center, funded by the Fonds National de la Recherche through a PEARL grant. His main focus is the development of novel mass spectrometry-based proteomics methodologies, and its application to biomarker discovery and evaluation, and to proteomics in general.
Previously, Bruno Domon was group leader and principal investigator at the Institute of Molecular Systems Biology at ETH Zurich heading the mass spectrometry laboratory and the biomarker program. As director at Celera Genomics in Rockville MD, USA he led the proteomics program on drug target discovery in oncology, which resulted in the identification of cell surface proteins for therapeutic development and diagnostics. Prior to that, he was associated director heading the mass spectrometry facility at Biogen in Cambridge MA, USA. He held different functions at Ciba-Geigy (now Novartis) in Basel, including the position of head of the mass spectrometry facility. He studied chemistry at the University of Neuchatel, where he obtained a chemical engineering degree. He graduated from the University of Lausanne in 1984. He started his mass spectrometry carrier as post-doctoral fellow at Ciba-Geigy in Basel and at the department of Chemistry of the Massachusetts Institute of Technology. He is author or co-author of more than 75 publications published in peer-reviewed journals and inventor of several patents or patent applications.